1. Introduction {#s0005}
===============

Extraintestinal infections, usually urinary tract infections (UTIs), represent a main source of morbidity and mortality globally ([@b0070]). *Escherichia coli* (*E. coli*) is reported to be the key cause of UTIs ([@b0065]), and the uropathogenic *E. coli* (UPEC), a subset of extraintestinal pathogenic *E. coli* (ExPEC) group, is associated with causing more than 80% of all UTIs ([@b0170]). Over the past twenty years, the antimicrobial resistance of ExPEC to first-line antibiotics, such as ciprofloxacin and amoxicillin, has increased markedly ([@b0070]). Additionally, an increased extended spectrum β-lactamase (ESBL) carriage has been reported among ExPEC strains ([@b0160]).

As reported in 2008, *E. coli* sequence type 131 (*E. coli* ST131) was described among ESBL-producing *E. coli* in many continents throughout the world, and it has disseminated to become the predominant ExPEC clone that drives multidrug resistance (MDR) globally ([@b0135]). *E. coli* ST131 is associated with fluoroquinolone (FQ)-resistance and CTX-M production, and is considered a main source of the spread of CTX-M-15 ESBL gene variant ([@b0140], [@b0150]). *E. coli* ST131 belongs to the phylogroup B2 ([@b0140]), and to the serotype O25b:H4 ([@b0135]), although some ST131 members of serotype O16:H5 have been identified ([@b0035]). ST131 harbors the *fimH* gene that associated with a remarkable degree of allelic diversity, and *fimH30* is the dominant *fimH* type ([@b0135]). ST131 *H30* subclone includes two important subsets (*H30*R and *H3*0Rx) ([@b0105], [@b0130], [@b0135]). The *H30R* isolates commonly display fluoroquinolone resistance ([@b0175]), while the *H30*Rx isolates frequently produce CTX-M ESBLs ([@b0135], [@b0175]).

With regard to virulence potential of ST131, although previous reports showed ST131 with moderate virulence capacity compared to other major ExPEC STs such as ST73 and ST127 ([@b0010], [@b0075]), high virulence potential among ST131 isolates has been identified ([@b0050]). In Saudi Arabia, few studies on the molecular epidemiology of MDR ExPEC isolates have been performed ([@b0005], [@b0010], [@b0020], [@b0180]). Most reports have found that *E. coli* ST131 was the most dominant ST among the tested ExPEC isolates, however the overall distribution of ExPEC STs was greatly variable ([@b0010], [@b0020], [@b0180]). Nonetheless, information on the local prevalence of *E. coli* ST131 subclones and their virulence capacity is very scarce.

Recent work conducted in our laboratory has investigated the antibiogram and ESBL carriage of 100 clinical UPEC isolates, and demonstrated that 67% of these isolates were MDR, that 33% of isolates were ESBL-producing and that the CTX-M-15 was the predominant CTX-M variant ([@b0015]). Here we determined and compared various molecular traits of non-ESBL-producing and ESBL-producing UPEC isolates including their ST131 status, phylogenetic groups and virulence capacity. We further sought to characterize the *E. coli* ST131 isolates to identify subclones they belong to, and to compare between these subclones in terms of ESBL carriage, phylogenetic distribution and virulence potential.

2. Methods {#s0010}
==========

2.1. Isolation of bacterial strains {#s0015}
-----------------------------------

In our research work, sixty *E. coli* urine isolates, thirty ESBL-producing and thirty non ESBL-producing, were involved and these isolates were obtained between January and March of 2018, from urine specimens of in-patients hospitalised at a tertiary hospital in Riyadh, Saudi Arabia. The antibiotic susceptibility patterns and ESBL gene carriage of these isolates have been previously described ([@b0015]). [Table 1](#t0005){ref-type="table"} shows information on the ESBL-producing *E. coli* isolates.Table 1Details on ESBL-producing *E. coli* isolates used in this study.Isolate IDFQ phenotype[a](#tblfn1){ref-type="table-fn"}MDR phenotype[b](#tblfn2){ref-type="table-fn"}ESBL gene type(s)ReferenceCTX-M-15TEMOXA[@b0015]U1S++−−U4R++−−U7R++−−U9R++−−U10R++−−U12R++−−U15R++−−U16S++−−U20R++−−U24R++−−U27R++−−U28R++−+U31R++−+U46R++−+U55R++++U57R++−−U63R++−+U66R+++−U68S++−−U71S++−−U73R++−+U74R++−−U75S+−+−U78R++−−U82R++++U85R++++U87R++−+U93S+++−U95R+−++U98R+++−[^1][^2]

2.2. Phylogenetic grouping {#s0020}
--------------------------

Phylogenetic groups were identified by multiplex polymerase chain reaction (PCR) as recommended by Clermont et al ([@b0040]).

2.3. Screening for *E. coli* ST131 and identification of its subclones {#s0025}
----------------------------------------------------------------------

Screening for *E. coli* ST131 status was performed using a triplex PCR assay that combines the identification of O25b and O16 ST131 clades using the primer sets and PCR conditions previously published ([@b0045], [@b0080], [@b0115]). Afterwards, *E. coli* ST131 isolates belonging to *H30* subclone and the *H30*Rx subset were determined using allele-specific PCRs ([@b0025], [@b0055]).

2.4. Detection of virulence-associated gene (VAG) carriage {#s0030}
----------------------------------------------------------

The presence of 20 VAGs was tested for all isolates using established PCR-based assays described previously ([@b0030], [@b0095], [@b0100], [@b0110], [@b0165]). The virulence scores of isolates were calculated as previously shown ([@b0145]). ExPEC status of all isolates was also identified using procedure from the previous reference study [@b0155].

2.5. Statistical analysis {#s0035}
-------------------------

IBM SPSS software (version 21.0) was employed for data analysis. Comparison study in different groups was conducted using Fisher's exact test (FET) and virulence scores were estimated by Mann-Whitney *U* test. *P* value of ≤0.05 used as threshold for statistical significance.

3. Results {#s0040}
==========

3.1. Characteristics of ESBL-producing and non ESBL-producing *E. coli* isolates {#s0045}
--------------------------------------------------------------------------------

Of all the 60 *E. coli* isolates, 6 (10%) were from phylogroup A, 5 (8.3%) from group B1, 37 (61.7%) from group B2, 0 (0%) from group C, 10 (16.7%) from group D, 0 (3.3%) from group E and 2 (3.3%) from group F ([Table 2](#t0010){ref-type="table"}). The association between phylogroup B2 and ESBL-producing isolates (*P* = 0.007) was statistically significant, however groups A and B1 were significantly found among non ESBL-producing *E. coli* isolates ([Table 2](#t0010){ref-type="table"}).Table 2Characteristics of *E. coli* isolates in relation to ESBL carriage.Number of isolates (%)CategorySpecific traitESBL-producing (*n* = 30)Non-ESBL-producing (*n* = 30)Total (*n* = 60)*P* value[a](#tblfn3){ref-type="table-fn"}PhylogroupsA0 (0%)6 (20%)6 (10%)**0.02**B10 (0%)5 (16.7%)5 (8.3%)**0.05**B224 (80%)13 (43.3%)37 (61.7%)**0.007**C0 (0%)0 (0%)0 (0%)1.000D6 (20%)4 (13.3%)10 (16.7%)0.73E0 (0%)0 (0%)0 (0%)1.000F0 (0%)2 (6.7%)2 (3.3%)0.49ST131 isolatesST13124 (80%)13 (43.3%)37 (61.7%)**0.007**ST131 O25b24 (80%)13 (43.3%)37 (61.7%)**0.007**ST131 O160 (0%)0 (0%)0 (0%)1.000ST131 subclonesST131 *H30*14 (46.7%)5 (16.7%)19 (31.7%)**0.03***H30*Rx7 (23.3%)2 (6.7%)9 (15%)0.15Non *H30*Rx7 (23.3%)3 (10%)10 (16.7%)0.3ST131 non- *H30*10 (33.3%)8 (26.7%)18 (30%)0.8FQ phenotypeFQ R[b](#tblfn4){ref-type="table-fn"}24 (80%)12 (40%)36 (60%)**0.003**MDR phenotypeMDR30 (100%)15 (50%)45 (75%)**\<0.001**Adhesions*papA*8 (26.7%)6 (20%)14 (23.3%)0.76*papC*8 (26.7%)6 (20%)14 (23.3%)0.76*papG* allele I0 (0%)0 (0%)0 (0%)1.000*papG* allele II7 (23.3%)5 (16.7%)12 (20%)0.75*sfa/focDE*2 (6.7%)2 (6.7%)4 (6.7%)1.000*afa/draBC*9 (30%)3 (10%)12 (20%)0.10*fimH*29 (96.7%)24 (80%)53 (88.3%)0.10*iha*19 (63.3%)14 (46.7%)33 (55%)0.30Siderophores*iutA*23 (76.7%)20 (66.7%)43 (71.6%)0.57*iroN~E.\ coli~*2 (6.7%)9 (30%)11 (18.3%)**0.04**Toxins*hlyA*6 (20%)4 (13.3%)10 (16.7%)0.73*cnf1*3 (10%)3 (10%)6 (10%)1.000Polysaccharide coatings*kpsMT* II17 (56.7%)14 (46.7%)31 (51.7%)0.60*kpsMT* III0 (0%)2 (6.7%)2 (3.3%)0.49Miscellaneous*PAI*19 (63.3%)9 (30%)28 (46.7%)**0.02***cvaC*1 (3.3%)4 (13.3%)5 (8.3%)0.35*traT*20 (66.7%)18 (60%)38 (63.3%)0.79*ompT*13 (43.3%)11 (36.7%)24 (40%)0.79*usp*17 (56.7%)11 (36.7%)28 (46.7%)0.19*sat*17 (56.7%)12 (40%)29 (48.3%)0.30ExPEC[c](#tblfn5){ref-type="table-fn"}23 (76.7%)15 (50%)38 (63.3%)0.06Virulence scores[d](#tblfn6){ref-type="table-fn"}6.8 (1--11)5.5 (1--13)6.2 (1--13)0.09[^3][^4][^5][^6][^7]

Our data found that 37 of 60 (61.7%) isolates belonged to the ST131 clone ([Table 2](#t0010){ref-type="table"}). Of these, 24 (80%) were ESBL-producing while only 13 (43.3%) were non ESBL-producing, and this difference was significant (*P* = 0.007). Additionally, screening the O16 and O25b ST131 clades revealed that all the 37 *E. coli* ST131 isolates (100%) were from O25b clade. Subclone typing of ST131 isolates showed that the *H30* was the most prevalent subclone, with 19 of 60 (31.7%) isolates were *H30*, while 18 (30%) belonged to subclones other than non *H30*. Among *H30* isolates, 10 (16.7%) were from *H30* non-Rx whereas 9 (15%) belonged to *H30*Rx subset.

We also found that ESBL-producing isolates were more capable of displaying FQ resistance and MDR phenotypes compared to non ESBL-producing isolates, and there was a statistically significant difference between ESBL-producing and non producing isolates in terms of FQ resistance (*P* = 0.003) and MDR phenotype (*P* ≤ 0.001) ([Table 2](#t0010){ref-type="table"}).

Considering the virulence capacity of all *E. coli* isolates, the most commonly expressed VAGs were *fimH*, *iutA*, *iha*, *traT* and *kpsMTII*, **and these were found** in ≥50% of the isolates. However, all *E. coli* isolates were negative for *papG* allele I. There was a slight difference in the virulence carriage between ESBL-producing and non ESBL-producing isolates, and the median virulence scores (ranges) were 6.8 (1--11) for ESBL-producing isolates and 5.5 (1--13) for non ESBL-producing isolates ([Table 2](#t0010){ref-type="table"}).

3.2. Characteristics of *E. coli* ST131 and non ST131 isolates {#s0050}
--------------------------------------------------------------

All 37 *E. coli* ST131 isolates (100%) were from B2 group. Most of the non ST131 isolates derived from group D followed by group A, while none of these isolates were derived from group B2. ST131 isolates were significantly associated with group B2 (*P* ≤ 0.001) ([Table 3](#t0015){ref-type="table"}).Table 3Characteristics of *E. coli* isolates in relation to clonal group.Number of isolates (%)CategorySpecific traitST131 (*n* = 37)Non-ST131 (*n* = 23)Total (*n* = 60)*P* value[a](#tblfn7){ref-type="table-fn"}PhylogroupsA0 (0%)6 (26.1%)6 (10%)**0.002**B10 (0%)5 (21.7%)5 (8.3%)**0.006**B237 (100%)0 (0%)37 (61.7%)**\<0.001**C0 (0%)0 (0%)0 (0%)1.000D0 (0%)10 (43.5%)10 (16.7%)**\<0.001**E0 (0%)0 (0%)0 (0%)1.000F0 (0%)2 (8.7%)2 (3.3%)0.15ESBL type(s)ESBL producing24 (64.9%)6 (26.1%)30 (50%)**0.007**CTX-M-1512 (32.4%)3 (13%)15 (25%)0.13CTX-M-15 + TEM1 (2.7%)2 (8.7%)3 (5%)0.55CTX-M-15 + OXA7 (18.8%)0 (0%)7 (11.7%)**0.04**CTX-M-15 + TEM + OXA3 (8.1%)0 (0%)3 (5%)0.28TEM0 (0%)1 (4.3%)1 (1.7%)0.38TEM + OXA1 (2.7%)0 (0%)1 (1.7%)0.38Non-ESBL13 (35.1%)17 (73.9%)30 (50%)**0.007**FQ phenotypeFQ R35 (94.6%)2 (8.7%)37 (61.7%)**\<0.001**MDR phenotypeMDR31 (83.7%)14 (60.9%)45 (75%)0.07Adhesions*papA*13 (35.1%)1 (4.3%)14 (23.3%)**0.005***papC*13 (35.1%)1 (4.3%)14 (23.3%)**0.005***papG* allele I0 (0%)0 (0%)0 (0%)1.000*papG* allele II12 (32.4%)0 (0%)12 (20%)**0.002***sfa/focDE*3 (8.1%)1 (4.3%)4 (6.7%)1.000*afa/draBC*9 (24.3%)3 (13%)12 (20%)0.34*fimH*36 (97.3%)17 (73.9%)53 (88.3%)**0.01***iha*25 (67.6%)8 (34.8%)33 (55%)**0.02**Siderophores*iutA*29 (78.4%)14 (60.9%)43 (71.6%)0.24*iroN~E.\ coli~*6 (16.2%)5 (21.7%)11 (18.3%)0.73Toxins*hlyA*10 (27%)0 (0%)10 (16.7%)**0.009***cnf1*6 (16.2%)0 (0%)6 (10%)0.07Polysaccharide coatings*kpsMT* II23 (62.2%)8 (34.7%)31 (51.7%)0.06*kpsMT* III0 (0%)2 (8.7%)2 (3.3%)0.14Miscellaneous*PAI*28 (75.7%)0 (0%)28 (46.7%)**\<0.001***cvaC*1 (2.7%)4 (17.4%)5 (8.3%)0.07*traT*23 (62.2%)15 (65.2%)38 (63.3%)1.000*ompT*20 (74.1%)4 (17.4%)24 (40%)**0.007***usp*26 (70.3%)2 (8.7%)28 (46.7%)**\<0.001***sat*22 (59.5%)7 (30.4%)29 (48.3%)**0.04**ExPEC[b](#tblfn8){ref-type="table-fn"}29 (78.4%)9 (39.1%)38 (63.3%)**0.005**Virulence scores[c](#tblfn9){ref-type="table-fn"}7.5 (1--13)4 (1--7)6.2 (1--13)**\<0.001**[^8][^9][^10][^11]

With regard to ESBL carriage, ST131 isolates were higher in their ability to carry ESBL genes than non-ST131 isolates. Our data found that 24 of 37 (64.9%) ST131 isolates were ESBL producers while ESBL production was only detected in 6 of 23 (26.1%) of non ST131 isolates, and the overall difference in ESBL carriage between ST131 and non ST131 isolates was significant (*P* = 0.007). ST131 isolates were significantly higher in their ability to exhibit FQ resistance than non ST131 isolates (*P* ≤ 0.001), while the difference between these groups in showing MDR phenotype was insignificant (*P* = 0.07) ([Table 3](#t0015){ref-type="table"}).

With respect to virulence capacity, compared to non ST131 isolates, *E. coli* ST131 isolates were linked to higher VAG carriage. ST131 isolates were significantly associated with carrying 8 VAGs, *papA*, *papC*, *papG* allele II, *fimH*, *iha*, *hlyA*, *PAI*, *ompT*, *usp* and *sat*, compared to non ST131 isolates. The median virulence scores (ranges) were 7.5 (1--13) for ST131 isolates and 4 (1--7) for non ST131 isolates, and this difference was found to be significant (*P* ≤ 0.001). The number of isolates showing ExPEC status was also significantly higher among ST131 isolates than that of non ST131 isolates (*P* = 0.005) ([Table 3](#t0015){ref-type="table"}).

3.3. Characteristics of *E. coli* ST131 subclones {#s0055}
-------------------------------------------------

ESBL carriage was detected in 14 of 19 (73.7%) *H30* isolates \[7 (77.8%) *H30*Rx and 7 (70%) *H30* non-Rx\], however ESBL production was found in 10 of 18 (55.6%) non *H30* isolates. Our data found that 19 *H30* isolates (100%) were FQ resistant while 16 (88.9%) of non *H30* isolates were FQ insusceptible. In contrast, MDR phenotype was more predominant in non *H30* compared to *H30* isolates. The difference between various ST131 subclones in their ESBL carriage, FQ phenotype and MDR phenotype remained insignificant ([Table 4](#t0020){ref-type="table"}).Table 4Characteristics of isolates belonging to various *E. coli* ST131 subclones.CategorySpecific traitST131 subclones, number of isolates (%)*P* value[a](#tblfn10){ref-type="table-fn"}*H30*Rx (9)*H30* non- Rx (10)Non *H30* (18)Total (37)*H30*Rx vs *H30* non-Rx*H30*Rx vs Non *H30H30* non-Rx vs Non *H30*ESBL type(s)ESBL producing7 (77.8%)7 (70%)10 (55.6%)24 (64.9%)1.0000.410.69CTX-M-153 (33.3%)5 (50%)4 (22.2%)12 (32.4%)0.640.380.08CTX-M-15 + TEM0 (0%)0 (0%)1 (5.55%)1 (2.7%)1.0001.0001.000CTX-M-15 + OXA2 (22.2%)2 (20%)3 (16.7%)7 (18.9%)1.0001.0001.000CTX-M-15 + TEM + OXA2 (22.2%)0 (0%)1 (5.55%)3 (8.1%)0.470.281.000TEM0 (0%)0 (0%)0 (0%)0 (0%)1.0001.0001.000TEM + OXA0 (0%)0 (0%)1 (5.55%)1 (2.7%)1.0001.0001.000Non-ESBL2 (22.2%)3 (30%)8 (44.4%)13 (35.1%)1.0000.410.69FQ phenotypeFQ R9 (100%)10 (100%)16 (88.9%)35 (94.6%)1.0000.540.52MDR phenotypeMDR7 (77.8%)8 (80%)16 (88.9%)31 (83.7%)1.0000.580.60Adhesions*papA*3 (33.3%)3 (30%)7 (38.9%)13 (35.1%)1.0001.0000.70*papC*3 (33.3%)3 (30%)7 (38.9%)13 (35.1%)1.0001.0000.70*papG* allele I0 (0%)0 (0%)0 (0%)0 (0%)1.0001.0001.000*papG* allele II3 (33.3%)3 (30%)6 (33.3%)12 (32.4%)1.0001.0001.000*sfa/focDE*0 (0%)1 (10%)2 (11.1%)3 (8.1%)1.0000.541.000*afa/draBC*2 (22.2%)4 (40%)3 (16.7%)9 (24.3%)0.631.0000.21*fimH*9 (100%)10 (100%)17 (94.4%)36 (97.3%)1.0001.0001.000*iha*9 (100%)10 (100%)6 (33.3%)25 (67.6%)1.000**0.0010.0009**Siderophores*iutA*9 (100%)10 (100%)10 (55.6%)29 (78.4%)1.000**0.030.03***iroN~E.\ coli~*0 (0%)1 (10%)5 (27.8%)6 (16.2%)1.0000.140.37Toxins*hlyA*1 (11.1%)3 (30%)6 (33.3%)10 (27%)0.580.361.000*cnf1*1 (11.1%)3 (30%)2 (11.1%)6 (16.2%)0.581.0000.32Polysaccharide coatings*kpsMT* II5 (55.6%)8 (80%)10 (55.6%)23 (62.2%)0.351.0000.25*kpsMT* III0 (0%)0 (0%)0 (0%)0 (0%)1.0001.0001.000Miscellaneous*PAI*9 (100%)10 (100%)9 (50%)28 (75.7%)1.000**0.010.001***cvaC*0 (0%)0 (0%)1 (5.6%)1 (2.7%)1.0001.0001.000*traT*9 (100%)8 (80%)6 (33.3%)23 (62.2%)0.47**0.0010.05***ompT*7 (77.8%)4 (40%)9 (50%)20 (74.1%)0.170.230.71*usp*9 (100%)9 (90%)8 (44.4%)26 (70.3%)1.000**0.0090.04***sat*6 (66.7%)10 (100%)6 (33.3%)22 (59.5%)0.090.12**0.0009**ExPEC[b](#tblfn11){ref-type="table-fn"}8 (88.9%)10 (100%)11 (61.1%)29 (78.4%)0.470.2**0.03**Virulence scores[c](#tblfn12){ref-type="table-fn"}8.9 (7--12)9.3 (7--12)5.9 (1--13)7.5 (1--13)0.65**0.030.009**[^12][^13][^14][^15]

Considering the virulence capacity of ST131 subclones, each of *H30* subsets (*H30*Rx and non-Rx) was significantly associated with 5 VAGs, *iha*, *iutA*, *PAI*, *traT* and *usp*, compared to non *H30* ([Table 4](#t0020){ref-type="table"}). Additionally, *H30* non-Rx subset was significantly associated with carrying the *sat* gene in comparison to non *H30*. Generally, *H30* non-Rx subset was the highest in terms of the virulence capacity compared to *H30*Rx and to non *H30*. The median virulence scores (ranges) were 9.3 (7--12) for non-Rx isolates, 8.9 (7--12) for ST131 *H30*Rx isolates and 5.9 (1--13) for non *H30* isolates. Our data also found a significant difference in the median virulence score between *H30* non-Rx and non *H30* isolates (*P* = 0.009). The number of isolates showing ExPEC status was also significantly higher among *H30* non-Rx compared to non *H30* (*P* = 0.03) ([Table 4](#t0020){ref-type="table"}).

4. Discussion {#s0060}
=============

*E. coli* ST131 has currently emerged as a major rapidly disseminated pandemic *E. coli* clone worldwide, with a high capability of causing extraintestinal infections, particularly UTIs ([@b0135]). Additionally, ST131 *H30* subclone known to be a major factor for MDR ExPEC illnesses ([@b0090]). This study explored the genotypic traits of *E. coli* urine isolates from Riyadh, Saudi Arabia, and provided comparisons between ESBL-producing and non-producing *E. coli* isolates, between *E. coli* ST131 and non ST131 isolates, and between different *E. coli* ST131 subclones.

Here we showed that most of our *E. coli* were derived from phylogenetic B2 group, this concurs with earlier reports showing the dominance of this phylogroup among ExPEC isolates that cause UTIs ([@b0100]). However, we found some isolates that derived from other groups such as D, A and B1. A previous report described the occurrence of significant shift toward other phylogenetic groups, particularly A and D, among FQ resistant and/or ESBL producing *E. coli* isolates ([@b0085]), and this might provide an explanation of the phylogenetic diversity detected among our *E. coli* isolates.

It was also found that ST131 clone accounted for 37 of 60 (61.7%) isolates, and this was higher compared to earlier local reports showing that the prevalence of ST131 isolates ranged between 17.3 and 37.5% ([@b0010], [@b0020], [@b0180]). Additionally, we demonstrated a significant association between ST131 isolates and ESBL-production, which is similar to a previous local finding ([@b0010]). Phylogenetically, all ST131 isolates identified in this study were derived from group B2, which agrees with many reports globally ([@b0090], [@b0135]). The high local dissemination of this clone reported here merits detailed future investigation to understand the reasons behind its success over other major STs.

Subclone typing of *E. coli* ST131 isolates was identified, with *H30* being the most common ST131 subclone. This was concordant with a previous local study ([@b0010]), and with other reports from China ([@b0120]) and United States ([@b0090]). Of the *H30* isolates, 10 (16.7%) were members of *H30* non-Rx subset while 9 (15%) belonged to *H30*Rx subset. However, there is no previous report on the prevalence of different *H30* subsets in Saudi Arabia. Our ST131 subclone typing results concur with recent findings from China ([@b0120]) and United States ([@b0090]) showing that the prevalence of *H30* non-Rx subset was higher that of *H30*Rx. As given the vast number of our *E. coli* ST131 isolates are FQ resistant (94.6%), the dominance of *H30* non-Rx subset among all *H30* members is expected since the *H30* subclone, particularly non-Rx subset, comprises most of the FQ-resistant ST131 isolates ([@b0175]). Additionally, we also found a strong association between ST131 *H30*Rx subset and CTX-M-15 production, which is consistent with many previous reports showing the frequent association between the *H30*Rx subset and CTX-M-15 carriage ([@b0135], [@b0175]).

Our data showing high virulence carriage of ESBL producers is in contrary to the previous finding showing that antimicrobial resistance was linked to a great reduction in virulence ([@b0085]). Additionally, given that 80% of ESBL producers in this study were FQ-resistant, this high virulence among ESBL-producing isolates seems to disagree with previous reports demonstrating higher virulence potential among FQ-susceptible ExPEC isolates compared to FQ-resistant isolates and ESBL-producing isolates ([@b0090]).

*E. coli* ST131 isolates tested here were significantly higher in terms of virulence score compared to non ST131 isolates, and this is in contrary to a previous local study showing ST131 isolates with a moderate virulence capacity compared to other ExPEC STs ([@b0010]). However, it concurs with previous reports showing high virulence potential of ST131 isolates ([@b0050]).

Among ST131 subclones, we found that the *H30* isolates were generally higher than non *H30* isolates in terms of the overall virulence carriage. Within *H30* subclone, *H30* non-Rx subset showed a slightly higher virulence score than *H30*Rx subset, and this disagrees with previous reports showing that the virulence carriage of *H30R*x isolates was higher than *H30* non-Rx isolates ([@b0090], [@b0120]). The finding of our study showing distinctive virulence genotypes and antimicrobial resistance phenotypes among different ST131 subclones highlights the need of testing the traits of these subclones individually instead of considering them as one ST131 group only.

Our study has limitations; firstly the number of isolates used here was low compared to some molecular epidemiological studies on *E. coli*, and this might be a caveat to our findings. Additionally, it was performed on a population from Riyadh and this might not reflect the prevalence of *E. coli* ST131 and its subclones in other regions within Saudi Arabia.

In conclusion, we provided the first local description of prevalence and traits of clinical *E. coli* ST131 main subclones. Our study showed high prevalence of ST131 among UPEC isolates locally. More importantly, it also demonstrated the presence of distinctive virulence genotypes and antimicrobial resistance phenotypes among different ST131 subclones, with ST131 *H30* isolates showing the highest virulence potential, ESBL carriage and FQ resistance. Given that the ST131 *H30* subclone has currently disseminated as a major cause of MDR infections, it would be essential to use rapid diagnostic tests to identify *E. coli* ST131 and its important subclones in the future. These tests can provide results in \<1 h, therefore allowing the guidance for empirical antibiotic selection. Additionally, carrying out comparative whole genome sequencing-based studies on ST131 and its subclones will significantly enhance our knowledge of factors that drive the success of these organisms.
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[^1]: R: resistant, S: susceptible.

[^2]: MDR phenotype refers to displaying resistance to at least 1 antibiotic in ≥3 antibiotic groups ([@b0125]).

[^3]: The bold numbers refer to presence of significant difference between groups for some traits.

[^4]: *P* values for 2-group comparison: ESBL and non ESBL.

[^5]: FQ resistant.

[^6]: Number of isolates showing ExPEC status.

[^7]: Median number of virulence factors (range).

[^8]: The bold numbers refer to presence of significant difference between groups for some traits.

[^9]: *P* values (by Fisher's exact test) are for 2-group comparison: ST131 and non ST131.

[^10]: Number of isolates showing ExPEC status.

[^11]: Median number of virulence factors (range).

[^12]: The bold numbers refer to presence of significant difference between groups for some traits.

[^13]: *P* values for 3-group comparisons: *H30*Rx, *H30* non-Rx and non *H30.*

[^14]: Number of isolates showing ExPEC status.

[^15]: Median number of virulence factors (range).
